Wednesday, 12 March 2008
12.00 a.m. Start of Registration (Hotel Regent)

BDA Immunotherapy Working Group (closed meeting):

Improving the effiacy of cancer Immunotherapy
What do we need to know? What can we measure?
A critical evaluation of currently determined immune parametres

This meeting is only for particular members of the BDA Immunotherapy Working Group. However we offer the possibility for a limited number of interested scientists to take part. If you are interested to join the meeting please enquire although we reserve the right to pre-elect.

1.00 - 1.20 p.m. Welcome and Introduction
Chair: L. Hakansson, S. Khleif
1.00 - 1.20



1.20 - 2.35 p.m.

1.20 - 1.45 p.m.



1.45 - 2.10 p.m.



2.10 - 2.35 p.m.
What do we need to know to improve the efficacy of
immunotherapy ?
L. Håkansson

Overview

Camouflage and sabotage: Tumour escape from immune
surveillance
R. Kiessling, Stockholm

Active immunotherapy of cancer – operational and biologic
challenges to making it work
L. Finke, Durham

Predicting responders to immunotherapy by intensive
immunomonitoring
H. Singh, Tübingen
2.35 - 3.00 p.m. Coffee Break
3:00 - 6:00 p.m. Monitoring immunotherapy
Chair: A. Hoos, C. Zielinski
3.00 - 3.25 p.m.




3.25 - 3.50 p.m.




3.50 - 4.15


4.15 - 4.40 p.m.



4.40 p.m. 5.05 p.m.


5.05 - 5.30



5.30 - 6.00
T-helper responses and establishment of long term
memory responses following vaccination with K-ras
and telomerase vaccines
G.Gaudernack

Monitoring the immunological responses to NY-ESO-1 vaccines
within the Cancer Vaccine Collaborative clinical
trials network
S.Gnjatic

Evaluation of the infl ammatory tumour infi ltrate
J.Talmagde

Standardization of T cell immunomonitoring - correct protocol
choices and additional sources of variation
C. Britten

Regulatory aspects
M. Schuessler-Lenz

The challenge of introducing new immunotherapy
K. Kallen


Round Table discussion
7:30 p.m. Welcome Reception (Hotel Regent)
   

Wednesday | Thursday | Friday | Saturday